Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Final Survival Outcomes of the Randomized Phase 3 PRODIGY Trial - Neoadjuvant Docetaxel, Oxaliplatin, & S-1 + Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Yoon-Koo Kang
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Yoon-Koo Kang
Login to view comments.
Click here to Login